Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Investigational Tdap Vaccine in Young Adults
NCT03958799Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jun 2019
- Primary completion
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of tdap vaccine in Tetanus, diphtheria and pertussis (9 arms), sponsored by Sanofi. Primary endpoints: Number of participants reporting immediate adverse events at 30 minutes, Number of participants reporting solicited injection sites or systemic reactions at 7 days and 10 more. Started Jun 2019; status: completed.
02
Drugs
tdap vaccine
03
Conditions
Tetanusdiphtheriapertussis
Beyond the preview
Go deeper on NCT03958799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03958799.